PATIENTS AND METHODS
The study included 31 patients with diagnosed arterial hypertension resistant to pharmacological treatment who consented to therapeutic RD. Patients were assigned to 2 groups. Group 1 consisted of 7 patients (6 men and 1 woman) with accessory renal arteries. Accessory renal arteries were defined according to Id et al 15 as the presence of more than 1 artery with a similar size arising directly from the aorta entering the kidney, or separation of a smaller artery from the main renal artery, or the presence of an additional smaller artery arising from the aorta and supplying a limited part of the kidney. Of the 7 patients, 5 had both the left and right accessory renal arteries, 1 had left accessory renal artery, and 1 had right accessory renal artery. Group 2 consisted of 24 patients (13 men and 11 women) with bilateral single renal arteries. In both groups, all arteries were patent. In group 2, 2 patients had arterial stenosis. The groups did not differ in terms of age, weight, height, or body mass index. The characteristics of patients are presented in TABLE 1 .
RD was performed with the Symplicity™ device (Medtronic Inc., Palo Alto, California, United States). 1, 3, 4 After the procedure, patients were assessed during prospective follow -up visits at 6, 12, 24, and 36 months.
All patients were fully informed about the procedure and gave written informed consent to participate in the study. The study protocol was approved by an institutional review board (2 separate ethics committee approvals because the patients participated in the SYMPLICITY HTN -1 and SYMPLICITY HTN -2 trials).
after the procedure. 3, 4 In contrast, the Simplicity HTN -3 trial 5 suggested that 6 months after RD there were no significant differences in the reduction of systolic BP in office or 24 -hour ambulatory measurements as compared with a sham control. However, a 3 -year follow -up in the Global Simplicity Registry showed a significant BP reduction after RD. 6 A trial by Rosa et al 7 showed that BP reduction after RD is comparable to intensified pharmacotherapy and that RD added to standardized stepped -care antihypertensive treatment additionally reduced BP compared with pharmacotherapy alone. 8 In addition to BP reduction, RD seems to offer more therapeutic benefits for selected groups of patients such as those with sleep apnea, 9 polycystic ovary syndrome, 10 and end--stage renal failure. 11 The results of a Polish research group showed a significant reduction in systolic BP, diastolic BP, and pulse pressure (PP) after percutaneous RD. No vascular or renal complications in any of the patients were observed.
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However, the results of the above studies also showed that, despite proper implementation of the procedures, the BP -lowering effect varies among patients, with some of them showing no response to treatment. The reason for this remains unknown. Some authors postulate that the presence of an accessory renal artery may result in the lack of treatment effects after RD. 13, 14 Therefore, the aim of this prospective study was to assess the BP -lowering effect after catheter--based RD in patients with accessory renal arteries in comparison with that in patients with bilateral single renal arteries during a 3 -year follow -up. According to the study protocol, a computed tomography scan was performed at 6 months to 1 year during the postoperative follow -up. No significant lesions in renal arteries were diagnosed. Two patients had renal artery stenosis of up to 30%, but these lesions had been already diagnosed during the preprocedural angiography. No atherosclerosis progression in any of these lesions was found over the 1 -year follow -up period. Statistical analysis Continuous variables were presented as mean ± SD or median and quartiles as appropriate. Categorical variables were presented as number (percentage). The ShapiroWilk test was used to assess the normality of continuous variables. To examine the differences between the study groups, the analysis of variance (for normally distributed variables) and the Friedman test (for nonnormally distributed variables) were used. To examine the differences between the 2 dependent groups, the t test (for normally distributed variables) and the Wilcoxon test (for nonnormally distributed variables) were used. The analysis was performed using Statistica 10 (StatSoft Poland, Kraków). Statistical significance was set at a P level of less than 0.05.
RESULTS
Changes in systolic BP, diastolic BP, and PP during the study for both patient groups are presented in FIGURE 1. patient, and the number of antihypertensive medications was increased in 1 patient.
Before renal denervation (baseline)
Inmedications at baseline in patients with accessory renal arteries (group 1) and single renal arteries (group 2) Variable Group 1 Group 2 P value Number of antihypertensive drugs, mean (SD) 3.9 (0.4) 3.8 (0.8) 0.
DISCUSSION
The results of this study show that RD is a successful treatment in long -term follow--up in patients with resistant hypertension with accessory renal arteries. However, a significant reduction was observed only for systolic BP. Resistant hypertension, in contrast to pseudoresistance hypertension in which there are several other reasons for uncontrolled hypertension, 16 is defined as BP that remains above the treatment goal despite the concomitant use of 3 antihypertensive medications of different classes (of which one should be a diuretic) in optimal doses.
17 Resistant hypertension is present in about 10% to 25% of treated hypertensive patients and is associated with a higher risk of cardiovascular morbidity, mortality, and worse prognosis compared with easily controlled hypertension.
18-21
RD is a novel therapeutic option for drug--resistant hypertension, initially performed by Krum et al 3 in 2009. The Symplicity I and Symplicity II trials (1 -year follow -up) have shown that 84% of the patients had durable lower BP. In Symplicity I, a reduction in systolic and diastolic BP was 25 and 11 mm Hg, respectively, and in Symplicity II, 28.1 and 9.7 mm Hg, respectively (P <0.001).
3,4 Two years after the procedure, a reduction in systolic and diastolic BP was 32 and 14 mm Hg, respectively, without serious events. In contrast to the previous studies, the Symplicity HTN -3 trial suggested that 6 months after RD there were no significant differences in the reduction of systolic BP in office or In group 1, there was a significant difference in systolic BP reduction (P = 0.025), while there were no significant differences in diastolic BP and PP reductions (P = 0.09 for both comparisons). In group 2, there were significant differences in systolic BP, diastolic BP, and PP reductions (P <0.001 for all comparisons). There were no significant differences in mean systolic BP, diastolic BP, and PP values between the study groups at 36 months after RD.
There were no significant changes in the mean number of antihypertensive medications or their doses during the follow -up (TABLE 2). In group 1, a reduction in medication doses was observed in 2 patients, and the number of antihypertensive medications was reduced in 1 patient. In group 2, a reduction of medication doses was observed in 2 patients, an increased dose was observed in 1 The outcomes of our study suggest that BP reduction is observed only in systolic BP in patients with accessory renal arteries. However, the lowering effect was also observed in diastolic BP and PP, but the results were not significant. In the group with bilateral arteries, the lowering effect was observed in systolic BP, diastolic BP, and PP (P <0.001). However, when we compared mean systolic BP, diastolic BP, and PP between the 2 groups 36 months after RD, no significant differences were observed. These differences may be explained by a small number of patients in group 1. The population in the study by Id et al 15 was larger (74 patients) than in our study (31 patients). However, the percentage of patients with accessory renal arteries was similar: 27% in the study by Id et al 15 and 23% in our study.
Additional differences between the studies were observed in the levels of baseline BP. In our study, baseline systolic and diastolic BP was higher than that in the study by Id et al 15 : in patients with accessory renal arteries, the values were 172.67 and 98.9 mm Hg, respectively, compared with 164.2 and 89.1 mm Hg, respectively; and in patients with bilateral single renal arteries, they were 175.57 and 100.1 mm Hg, respectively, compared with 166.2 and 89.4 mm Hg, respectively. When comparing the levels of BP reduction at 6 months between the studies, higher BP reduction was observed in our study than in the study by Id et al 15 both in patients with accessory renal arteries (systolic and diastolic BP, 26.94 and 19.18 mm Hg, respectively, compared with 6.2 and 0.2 mm Hg, respectively) and in patients with bilateral single renal artery (systolic and diastolic BP, 25.99 and 10.47 mm Hg, respectively, compared with 16.6 and 6.7 mm Hg, respectively). Of note, in the study by Id et al, 15 the decrease in BP levels in patients with accessory renal arteries was statistically significant. Thus, a smaller sample size and higher BP values at baseline probably explain the discrepancies between the results. It should also be noted that our study had a much longer follow -up (36 months) than the study by Id et al 15 (6 months), which might be another reason for the observed differences.
To our knowledge, our study was the first to compare the PP -lowering effects in patients with accessory renal arteries and in those with bilateral single renal arteries. Importantly, the first clinical RD trials (Symplicity I and Symplicity II) did not include patients with accessory renal arteries. The presence of more than 1 main renal artery was one of the exclusion criteria for the trials. For this reason, further randomized controlled trials on a large number of patients are needed.
As shown by numerous clinical studies, any new pharmacological drugs should be introduced carefully to avoid adverse events or interactions with other drugs or diseases.
26 Therefore, alternative treatment options, including RD, are considered to be promising for patients with resistant hypertension.
24 -hour ambulatory measurements as compared with a sham control. 5 However, there are several limitations of the study design that might have influenced the clinical outcomes. 22, 23 Importantly, the long -term results of the Global Symplicity Registry trial confirmed that RD significantly reduced BP 3 years after the procedure, 6 which was also corroborated by our study.
In both groups, no modification of antihypertensive treatment was observed. The DENERHTN study 8 showed that RD in combination with standardized stepped -care antihypertensive treatment results in a greater decrease in ambulatory BP than the standardized treatment alone at 6 months. The 6 -month results of the Prague -15 Study showed that RD led to a reduction of BP comparable to intensified pharmacotherapy. 7 Unfortunately, in some patients, the BP--lowering effect was insufficient, and, according to study results, 10% to 13% of the patients did not respond to treatment. 2, 3 The reason for this remains unknown; however, some authors suspect that the nonresponse to treatment is related to the renal vascular anatomy. 13, 14 It has been hypothesized that accessory renal arteries, which are seen in 25% to 50% of the population (according to autopsy data), are related to the risk of hypertension via activation of the renin-angiotensinaldosterone system. 23, 24 Isolated stenosis or occlusion of accessory renal arteries with a patent main renal trunk can result in renovascular hypertension. However, Kuczera et al 25 showed that stenosis of the accessory artery is rare (0.8%). 25 Their magnetic resonance imaging study revealed no significant differences in the prevalence of renal artery stenosis between patients with and those without accessory renal arteries, which seems to refute the previous hypotheses.
Following Id et al, 15 renal sympathetic nerves are located primarily in the adventitia of all arteries supplying the kidneys, regardless of whether these are accessory renal arteries or bilateral single renal arteries. Therefore, the most plausible explanation is a more incomplete interruption of the renal sympathetic fibers in patients with accessory renal arteries, either due to an inability to denervate all accessory renal arteries or due to a more conservative approach in smaller arteries because circumferential catheter manipulation is not always safe. Moreover, accessory renal arteries, including dual renal arteries and early separation of pole arteries, are frequently smaller than 4 mm. Therefore, these arteries are mostly not available to ablation with currently approved devices. Due to incomplete denervation, BP reduction may be less effective compared with single renal artery denervation.
15

Id et al
15 first compared the BP -lowering effect after RD in patients with accessory renal arteries and in patients with bilateral single arteries (54 patients).
12 After a 6 -month follow -up, BP reduction was more effective in patients with bilateral single renal arteries. 20 Our long -term results support this observation.
Conclusions RD successfully reduced systolic BP in patients with resistant hypertension and accessory renal artery. PP reduction achieved after RD in patients with accessory renal arteries is less pronounced than that in patients with bilateral single renal arteries. At primary endpoint of the study and at 36 months, the difference in BP -lowering effects between the groups was only 3.97 mm Hg, and the results had no statistical significance.
